secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009653
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA lays out 2026 goals: darovasertib PFS data Q1, three Phase 3 trials, IDE849 registrational start
--------------------------------------------------------------------------------

- Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.
- Darovasertib to be in three randomized Phase 3 trials (OptimUM-02, -10, -11) across UM stages by H1 2026.
- IDE849 (DLL3 TOP1 ADC) registrational monotherapy study in SCLC/NEC targeted to start by end of 2026.
- IDE034 (B7H3/PTK7 ADC) Phase 1 dose escalation to begin Q1 2026; IDE892 (PRMT5) Phase 1 in Q1 2026.
- Cash of $1.1 billion as of Sep 30, 2025, expected to fund operations into 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/0001193125-26-009653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/d93674d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer